Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA4 | P22748 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL902931 | 1.00 | ALDH1A1 (0.56) | ALDH1A1FNTAFNTBCA1CA2 | |
| SCHEMBL3107844 | 1.00 | ALDH1A1 (0.56) | ALDH1A1FNTAFNTBCA1CA2 | |
| SCHEMBL15625954 | 0.81 | CA1 (0.53) | FNTAFNTBCA1CA2CA4 | |
| SCHEMBL21034464 | 0.78 | FAAH (0.42) | CA1CA2CA4CA9ABCB1 | |
| SCHEMBL21034463 | 0.78 | FAAH (0.42) | CA1CA2CA4CA9ABCB1 | |
| SCHEMBL7130391 | 0.77 | CA1 (0.42) | ALDH1A1CA1CA2CA4CA9 | |
| SCHEMBL7130401 | 0.77 | CA1 (0.42) | ALDH1A1CA1CA2CA4CA9 | |
| SCHEMBL7121380 | 0.77 | L3MBTL1 (0.59) | ALDH1A1CA1CA2CA4CA9 | |
| SCHEMBL7121377 | 0.77 | L3MBTL1 (0.59) | ALDH1A1CA1CA2CA4CA9 | |
| SCHEMBL7130397 | 0.76 | SMN1; SMN2 (0.46) | FNTAFNTBCA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014057498-A2 | PROCESS FOR THE PREPARATION OF COBICISTAT INTERMEDIATES | Mylan Laboratories Ltd. (IN) | 2014-04-17 | — | — | WO | claimed |
| CN-119350166-A | Preparation method and application of desmethylselegiline | 安徽贝克制药股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-110642721-B | Preparation method of selegiline hydrochloride | 安徽贝克生物制药有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-110668952-A | Preparation method of benzphetamine hydrochloride | 安徽贝克联合制药有限公司 | 2020-01-10 | — | — | CN | disclosed |
| CN-110642721-A | Preparation method of selegiline hydrochloride | 安徽贝克生物制药有限公司 | 2020-01-03 | — | — | CN | disclosed |
| US-9428473-B2 | Methods and intermediates for preparing pharmaceutical agents | GILEAD SCIENCES, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| EP-3009434-A1 | METHOD OF PREPARING AN INHIBITOR OF CYTOCHROME P450 MONOOXYGENASE, AND INTERMEDIATES INVOLVED | GILEAD SCIENCES, INC. (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20160002186-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. | 2016-01-07 | — | — | US | disclosed |
| EP-2414325-B1 | METHOD OF PREPARING AN INHIBITOR OF CYTOCHROME P450 MONOOXYGENASE, AND INTERMEDIATES INVOLVED. | GILEAD SCIENCES INC (US) | 2015-08-26 | — | — | EP | disclosed |
| US-9115100-B2 | Methods and intermediates for preparing pharmaceutical agents | GILEAD SCIENCES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150005493-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. | 2015-01-01 | — | — | US | disclosed |
| US-8853210-B2 | Methods and intermediates for preparing pharmaceutical agents | GILEAD SCIENCES, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| WO-2014057498-A2 | PROCESS FOR THE PREPARATION OF COBICISTAT INTERMEDIATES | Mylan Laboratories Ltd. (IN) | 2014-04-17 | — | — | WO | disclosed |
| US-20140088304-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8497396-B2 | Methods and intermediates for preparing pharmaceutical agents | GILEAD SCIENCES, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| EP-2414325-A2 | METHOD OF PREPARING AN INHIBITOR OF CYTOCHROME P450 MONOOXYGENASE, AND INTERMEDIATES INVOLVED | Gilead Sciences, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20100256366-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. | 2010-10-07 | — | — | US | disclosed |
| WO-2010115000-A2 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005493-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | CYP2F1, UGT1A1, CYP3A7 | ALDH1A1 160/4885FNTA 309/4885FNTB 1340/4885 |
| US-20100256366-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | CYP2F1, UGT1A1, CYP3A7 | ALDH1A1 160/4885FNTA 309/4885FNTB 1340/4885 |
| US-20140088304-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | CYP2F1, UGT1A1, CYP3A7 | ALDH1A1 160/4885FNTA 309/4885FNTB 1340/4885 |
| US-20160002186-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | CYP2F1, UGT1A1, CYP3A7 | ALDH1A1 160/4885FNTA 309/4885FNTB 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.